See more : Taeyang Metal Industrial Co., Ltd. (004105.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Ipsen S.A. (IPSEY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ipsen S.A., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- DeepSpatial Inc. (DSAIF) Income Statement Analysis – Financial Results
- Vinda International Holdings Limited (VDAHY) Income Statement Analysis – Financial Results
- Madhav Marbles and Granites Limited (MADHAV.BO) Income Statement Analysis – Financial Results
- Hangzhou Electronic Soul Network Technology Co., Ltd. (603258.SS) Income Statement Analysis – Financial Results
- Infrea AB (INFREA.ST) Income Statement Analysis – Financial Results
Ipsen S.A. (IPSEY)
About Ipsen S.A.
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.31B | 3.16B | 3.00B | 2.69B | 2.69B | 2.35B | 2.01B | 1.67B | 1.52B | 1.33B | 1.28B | 1.28B | 1.23B | 1.17B | 1.11B | 1.04B | 993.76M | 861.68M | 788.71M | 723.99M |
| Cost of Revenue | 571.20M | 527.70M | 538.00M | 490.60M | 488.00M | 454.20M | 385.60M | 353.30M | 336.80M | 310.00M | 253.39M | 254.77M | 249.24M | 236.19M | 237.81M | 219.93M | 199.03M | 181.38M | 176.83M | 176.31M |
| Gross Profit | 2.74B | 2.63B | 2.46B | 2.20B | 2.20B | 1.89B | 1.63B | 1.32B | 1.18B | 1.02B | 1.03B | 1.02B | 985.67M | 934.11M | 874.58M | 818.18M | 794.73M | 680.30M | 611.88M | 547.68M |
| Gross Profit Ratio | 82.72% | 83.28% | 82.06% | 81.74% | 81.88% | 80.66% | 80.83% | 78.86% | 77.85% | 76.73% | 80.23% | 80.06% | 79.82% | 79.82% | 78.62% | 78.81% | 79.97% | 78.95% | 77.58% | 75.65% |
| Research & Development | 619.30M | 445.30M | 428.40M | 405.60M | 388.80M | 302.10M | 265.80M | 208.90M | 192.60M | 186.90M | 259.05M | 248.55M | 253.59M | 221.13M | 197.29M | 182.92M | 184.74M | 178.35M | 167.57M | 140.79M |
| General & Administrative | 217.80M | 205.80M | 199.60M | 187.80M | 181.40M | 165.70M | 140.80M | 129.40M | 122.90M | 111.20M | 103.82M | 99.09M | 101.47M | 98.25M | 88.46M | 85.90M | 80.43M | -232.58M | -225.80M | -318.06M |
| Selling & Marketing | 917.10M | 833.40M | 835.70M | 784.00M | 838.60M | 787.40M | 715.90M | 608.40M | 541.40M | 464.10M | 451.27M | 473.48M | 425.15M | 422.81M | 396.14M | 358.40M | 321.05M | 307.80M | 292.59M | 319.24M |
| SG&A | 1.13B | 1.04B | 1.04B | 971.80M | 1.02B | 953.10M | 856.70M | 737.80M | 664.30M | 575.30M | 555.09M | 572.57M | 526.62M | 521.06M | 484.61M | 444.30M | 401.48M | 75.22M | 66.79M | 1.18M |
| Other Expenses | 165.00M | 273.00M | 119.10M | 97.70M | 132.90M | 82.70M | 102.40M | -21.70M | -7.20M | -9.20M | -6.26M | -20.21M | 7.92M | 12.76M | -3.47M | -677.00K | 17.41M | -12.62M | -2.62M | -1.58M |
| Operating Expenses | 1.92B | 1.76B | 1.58B | 1.48B | 1.54B | 1.34B | 1.22B | 968.40M | 868.20M | 771.10M | 824.79M | 847.08M | 788.13M | 705.15M | 702.11M | 635.48M | 585.85M | 485.82M | 450.71M | 411.01M |
| Cost & Expenses | 2.49B | 2.29B | 2.12B | 1.97B | 2.03B | 1.79B | 1.61B | 1.32B | 1.21B | 1.08B | 1.08B | 1.10B | 1.04B | 941.35M | 939.91M | 855.41M | 784.88M | 667.19M | 627.55M | 587.32M |
| Interest Income | 18.30M | 500.00K | 2.90M | 2.30M | 2.60M | 3.90M | 1.10M | 1.20M | 1.10M | 1.40M | 1.35M | 1.67M | 1.75M | 2.24M | 2.70M | 21.43M | 11.54M | 2.60M | -1.38M | 0.00 |
| Interest Expense | 37.70M | 18.50M | 23.70M | 27.50M | 31.40M | 10.20M | 11.20M | 7.00M | 3.90M | 5.90M | 4.82M | 5.37M | 1.76M | 1.59M | 4.40M | 4.35M | 13.49M | 2.48M | 6.53M | 0.00 |
| Depreciation & Amortization | 87.90M | 201.30M | 246.40M | 234.70M | 161.20M | 142.60M | 97.90M | 49.10M | 43.70M | 50.20M | 25.75M | 72.56M | 114.69M | 39.39M | 44.94M | 50.65M | 41.23M | 49.94M | 28.87M | 35.02M |
| EBITDA | 887.10M | 1.07B | 1.06B | 794.60M | 153.30M | 646.80M | 487.70M | 343.90M | 284.90M | 262.40M | 232.00M | 198.19M | 148.00M | 166.37M | 216.64M | 246.78M | 258.80M | 237.76M | 190.41M | 161.42M |
| EBITDA Ratio | 26.83% | 38.09% | 36.99% | 35.51% | 31.65% | 29.12% | 24.44% | 23.33% | 23.57% | 22.02% | 17.76% | 19.30% | 22.64% | 22.77% | 19.48% | 23.00% | 26.32% | 28.79% | 24.07% | 22.30% |
| Operating Income | 816.00M | 729.90M | 849.50M | 719.00M | 691.10M | 519.40M | 397.20M | 304.70M | 244.00M | 221.40M | 190.75M | 114.80M | 75.78M | 128.80M | 172.47M | 180.09M | 208.89M | 187.22M | 161.69M | 125.92M |
| Operating Income Ratio | 24.68% | 23.12% | 28.33% | 26.77% | 25.67% | 22.12% | 19.74% | 18.23% | 16.05% | 16.62% | 14.88% | 8.99% | 6.14% | 11.01% | 15.50% | 17.35% | 21.02% | 21.73% | 20.50% | 17.39% |
| Total Other Income/Expenses | -54.50M | -23.80M | -35.50M | 6.30M | -1.40M | -25.40M | -26.50M | -6.90M | -6.70M | -15.10M | -9.00M | 5.45M | -3.94M | -3.41M | -5.16M | 1.07M | -2.03M | -1.54M | -6.68M | -10.28M |
| Income Before Tax | 761.50M | 706.10M | 814.40M | 528.60M | -38.70M | 494.00M | 370.70M | 297.80M | 237.30M | 206.30M | 181.77M | 120.26M | 41.37M | 125.40M | 167.31M | 181.16M | 206.86M | 185.68M | 155.01M | 115.64M |
| Income Before Tax Ratio | 23.03% | 22.37% | 27.15% | 19.68% | -1.44% | 21.04% | 18.43% | 17.82% | 15.61% | 15.48% | 14.18% | 9.41% | 3.35% | 10.71% | 15.04% | 17.45% | 20.82% | 21.55% | 19.65% | 15.97% |
| Income Tax Expense | 136.20M | 112.30M | 168.20M | -17.80M | 19.60M | 108.10M | 101.40M | 73.50M | 49.80M | 53.80M | 39.56M | 24.44M | -13.34M | 16.96M | 10.59M | 33.32M | 54.48M | 40.89M | 32.64M | 40.24M |
| Net Income | 644.40M | 648.60M | 646.60M | 548.00M | -58.30M | 389.50M | 272.30M | 225.90M | 189.90M | 153.50M | 152.54M | -29.49M | 424.00K | 95.68M | 157.17M | 147.67M | 151.07M | 144.01M | 119.23M | 83.00M |
| Net Income Ratio | 19.49% | 20.55% | 21.56% | 20.40% | -2.17% | 16.59% | 13.54% | 13.52% | 12.49% | 11.52% | 11.90% | -2.31% | 0.03% | 8.18% | 14.13% | 14.22% | 15.20% | 16.71% | 15.12% | 11.46% |
| EPS | 7.09 | 1.97 | 1.96 | 1.65 | -0.17 | 1.17 | 0.82 | 0.68 | 0.57 | 0.47 | 0.46 | -0.09 | 0.00 | 0.28 | 0.47 | 0.44 | 0.45 | 0.43 | 0.35 | 0.25 |
| EPS Diluted | 7.40 | 1.95 | 1.94 | 1.64 | -0.17 | 1.17 | 0.82 | 0.68 | 0.57 | 0.47 | 0.46 | -0.09 | 0.00 | 0.28 | 0.47 | 0.44 | 0.45 | 0.43 | 0.35 | 0.25 |
| Weighted Avg Shares Out | 87.08M | 329.66M | 330.59M | 331.86M | 334.03M | 332.99M | 332.12M | 330.49M | 330.81M | 328.88M | 332.65M | 333.84M | 333.86M | 338.05M | 337.21M | 336.06M | 335.89M | 336.86M | 336.10M | 336.10M |
| Weighted Avg Shares Out (Dil) | 83.38M | 332.39M | 333.43M | 333.79M | 334.03M | 332.99M | 332.12M | 330.49M | 330.81M | 328.88M | 332.65M | 333.84M | 333.86M | 338.05M | 337.21M | 336.06M | 335.89M | 336.86M | 336.10M | 336.10M |
Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen
GENFIT: Ipsen's Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval
Ipsen's Iqirvo Shows Strong Start in Primary Biliary Cholangitis, Now Faces Rivalry from Gilead's Livdelzi
GENFIT: Positive Opinion from EMA Committee for Ipsen's Iqirvo® (elafibranor) in Primary Biliary Cholangitis
Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis
Annual General Meeting of Ipsen S.A. held on 28 May 2024
Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.'s Annual General Meeting on 28 May 2024
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting
Source: https://incomestatements.info
Category: Stock Reports